Drugs / Losmapimod
Trials 26 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT05002231 | Aug → Oct 2021 | — | Fulcrum Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT01756495 | Jan → Apr 2013 | acute coronary syndrome | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01648192 | Jul → Oct 2012 | acute coronary syndrome | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01039961 | Feb → Apr 2010 | cardiovascular disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00599612 | Jan → Feb 2008 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00549653 | Oct → Dec 2007 | atherosclerosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 217 trials | ||||||
| Phase 2 | NCT04264442 | Feb 2020 → Nov 2024 | facioscapulohumeral muscular dystrophy | Fulcrum Therapeutics | Terminated | No outcome recorded |
| Phase 2 | NCT04004000 | Aug 2019 → Oct 2024 | facioscapulohumeral muscular dystrophy 1 | Fulcrum Therapeutics | Terminated | No outcome recorded |
| Phase 2 | NCT04003974 | Aug 2019 → Jan 2021 | facioscapulohumeral muscular dystrophy | Fulcrum Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT02299375 | Dec 2014 → Jun 2016 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT02000440 | Jul 2014 → Feb 2016 | focal segmental glomerulosclerosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01218126 | Nov 2010 → Dec 2011 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01110057 | Jan → Aug 2010 | neuropathy, painful | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00910962 | Oct 2009 → Mar 2012 | acute coronary syndrome | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00976560 | Sep 2009 → Jul 2010 | major depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00969059 | Aug 2009 → Jul 2010 | neuropathy, painful | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00633022 | Jun 2008 → Dec 2009 | atherosclerosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00642148 | Feb 2008 → Jul 2009 | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00569062 | Sep 2007 → Jun 2008 | major depressive disorder | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 2 | NCT00474864 | Jul 2007 → Apr 2008 | hyperlipidemia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00393146 | Oct 2006 → Jan 2008 | rheumatoid arthritis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00392587 | Aug 2006 → ? | chronic obstructive pulmonary disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00256919 | Nov 2005 → Nov 2006 | rheumatoid arthritis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05397470 | Jun 2022 → Nov 2024 | facioscapulohumeral muscular dystrophy | Fulcrum Therapeutics | Terminated | No outcome recorded |
| Phase 3 | NCT04511819 | Aug 2020 → Mar 2021 | COVID-19 | Fulcrum Therapeutics | Terminated | No outcome recorded |
| Phase 3 | NCT02145468 | Jun 2014 → Dec 2015 | acute coronary syndrome | GlaxoSmithKline | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01541852 Comparator | Jun 2012 → Feb 2014 | chronic obstructive pulmonary disease | Cambridge University Hospitals NHS Foundation Trust | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 32 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | losmapimod | “evaluates the safety and efficacy of losmapimod (GW856553), a potent oral p38MAPK inhibitor, vs placebo in patients with non-ST-segment elevation myocardial infarction expected...” PMID 23137494 ↗ Oct 201216“p38α/β MAPK inhibitor (losmapimod; GW856553)” PMID 21262998 ↗ Jan 2011 |
| Known as | FTX-1821 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1088752 ↗ |
| Known as | GSK-AHAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL1088752 ↗ |
| Known as | GW856553 | “A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod (GW856553) Tablets...” NCT01218126 ↗13“Safety and Efficacy Study of Losmapimod (GW856553) in Frequently Exacerbating Participants With Chronic Obstructive Pulmonary Disease (COPD)” NCT02299375 ↗ “The dose of GW856553 will be 7.5 mg BID.” NCT01110057 ↗ “Phase I Study of GW856553 (Losmapimod)” NCT01648192 ↗ |
| Known as | GW856553X | “Losmapimod (micronized GW856553X) will be supplied as a film coated white, 7 mm round, biconvex, plain faced, tablet.” NCT02000440 ↗ |
| Action | Inhibit | “MAP kinase p38 alpha inhibitor” CHEMBL1088752 ↗2“MAP kinase p38 beta inhibitor” CHEMBL1088752 ↗ “inhibiting p38 MAPK activity” PMID 21262998 ↗ Jan 2011 |
| Modality | Small molecule | “losmapimod (a small molecule that inhibits p38α MAPK, a regulator of DUX4 expression, and p38β MAPK)” PMID 38631764 ↗ May 2024 |
| Route | Oral | “will be delivered as 100mL of a 0.1mg/mL GW856553/0.5 µCi/mL oral solution.” NCT00599612 ↗ |
| Target | DUX4 | “able to reduce aberrant expression of DUX4 in vitro” PMID 41649965 ↗ Feb 2026 |
| Target | MAPK11 | “MAP kinase p38 beta inhibitor” CHEMBL1088752 ↗ |
| Target | MAPK14 | “MAP kinase p38 alpha inhibitor” CHEMBL1088752 ↗ |